Necrotizing Enterocolitis

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

IB
2 programs
1
1
IBP-9414Phase 31 trial
IBP-9414Phase 21 trial
Active Trials
NCT02472769CompletedEst. Aug 2017
NCT03978000Active Not RecruitingEst. Jul 2024
Leadiant Biosciences
Leadiant BiosciencesMD - Rockville
1 program
1
STP206Phase 11 trial
Active Trials
NCT01954017Completed103Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Infant Bacterial TherapeuticsIBP-9414
Infant Bacterial TherapeuticsIBP-9414
Leadiant BiosciencesSTP206

Clinical Trials (3)

Total enrollment: 103 patients across 3 trials

NCT03978000Infant Bacterial TherapeuticsIBP-9414

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Start: Jul 2019Est. completion: Jul 2024
Phase 3Active Not Recruiting
NCT02472769Infant Bacterial TherapeuticsIBP-9414

IBP-9414 for the Prevention of Necrotizing Enterocolitis

Start: May 2016Est. completion: Aug 2017
Phase 2Completed
NCT01954017Leadiant BiosciencesSTP206

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

Start: Jan 2014Est. completion: Oct 2018103 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space